|
- Regeneron | Pushing the Bounds of Science
Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines Join our team and explore clinical trials
- About Regeneron | Our Company
Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases
- Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to . . .
TARRYTOWN, N Y , June 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) today announced interim results from the ongoing Phase 2 COURAGE trial investigating novel combinations of semaglutide (GLP-1 receptor agonist) and trevogrumab (anti-GDF8 anti-myostatin) with or without garetosmab (anti-activin A) for the treatment of obesity The trial demonstrated that
- PUSH THE BOUNDS OF SCIENCE - Regeneron
Regeneron is a leading biotechnology company dedicated to inventing, developing and commercializing life-transforming medicines for people with serious diseases
- Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025
Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks Find out why REGN stock is upgraded to buy
- US FDA approves Regenerons blood cancer therapy - MSN
By Puyaan Singh (Reuters) -Regeneron Pharmaceuticals said on Wednesday the U S Food and Drug Administration has approved its drug for a type of blood cancer called multiple myeloma that has
- Regeneron snags FDA nod for myeloma bispecific Lynozyfic
Another BCMA-targeted agent has arrived for the treatment of multiple myeloma | After a delay, Regeneron’s BCMA-directed bispecific antibody Lynozyfic has won an FDA approval with a more
- Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now The company secured accelerated FDA approval for Lynozyfic (linvoseltamab-gcpt) on July
|
|
|